



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/524,486

11/17/2005

Stefan Laufer

264821US0PCT

6298

22850

7590

05/27/2008

OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER

MORRIS, PATRICIA L

ART UNIT

PAPER NUMBER

1625

NOTIFICATION DATE

DELIVERY MODE

05/27/2008

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

DETAILED ACTION

Claims 16-37 are under consideration in this application.

The petition decision mailed April 18, 2008 is noted. The advisory action mailed March 14, 2008 is hereby vacated. The finality of the Office action mailed on December 11, 2007 is hereby maintained.

In order to clarify the record, applicants' appeal brief had NOT been in the record as incorrectly alleged by applicants when the advisory action was turned in by the examiner. The examiner did NOT address applicants' traversal of the currently pending rejections because the appeal brief had not been entered into the file. Applicants filed an appeal brief on March 4, 2008 well after their amendment after final on February 26, 2008.

The amendment filed after the final rejection on February 26, 2008 will NOT be entered for the reasons clearly set forth in the petition decision. Note page 5 where it is clearly stated that applicant's request to enter the proposed claim amendments filed after the final Office action on February 28, 2006 is denied. Hence, the claims filed on October 1, 2007 are under consideration herein.

Election/Restrictions

The restriction requirement is deemed sound and proper and is hereby made FINAL.

Again, this application has been examined to the extent readable on the elected compound wherein R¹⁰ represents a tetrahydropyran and nonheterocyclic groups, B represents nonheterocyclic groups and R¹-R⁷, A, m and n as set forth in claim 25, exclusively. Again, claims 24 and 34 have been examined to the extent readable on the treatment of rheumatoid arthritis.

Claim Rejections - 35 USC § 103

The rejection is hereby withdrawn with respect to the **elected compounds only** in response to applicants' assertions in the instant brief.

Claim Rejections - 35 USC § 112

Only claims drawn to the **treatment of rheumatoid arthritis would be allowable** in view of applicant's allegations in the instant response.

Double Patenting

The rejection of claims 16-34 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8, 10, 13 and 14 of U.S. Patent No. 6,432,988 in view of applicants' arguments in the instant brief.

Claims 16-23, 25-33 and 35 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12, 14 and 17 of copending Application No. 10/514,911. Although the conflicting claims are not identical, they are not patentably distinct from each other because for the reasons set forth in the previous Office action.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The claims in the instant application are not allowable and hence, this above rejection is maintained.

Allowable Subject Matter

Claims 24 and 34 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base

Art Unit: 1625

claim and any intervening claims and rewritten directed solely to the treatment of rheumatoid arthritis.

Claims 36 and 37 presented in independent form or made dependent on an allowable claim, would appear allowable, otherwise it is objected to as being dependent on a nonallowed claim. It is also noted that they will be substantial duplicates.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia L. Morris whose telephone number is (571) 272-0688. The examiner can normally be reached on Mondays through Fridays.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Patricia L. Morris/
Primary Examiner, Art Unit 1625

plm
May 19, 2008

Application/Control Number: 10/524,486
Art Unit: 1625

Page 5

Application/Control Number: 10/524,486
Art Unit: 1625

Page 6

Application/Control Number: 10/524,486
Art Unit: 1625

Page 7

Application/Control Number: 10/524,486
Art Unit: 1625

Page 8

Application/Control Number: 10/524,486
Art Unit: 1625

Page 9